These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21824093)

  • 21. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel vaccine vectors for HIV-1.
    Barouch DH; Picker LJ
    Nat Rev Microbiol; 2014 Nov; 12(11):765-71. PubMed ID: 25296195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.
    Hu H; Eller MA; Zafar S; Zhou Y; Gu M; Wei Z; Currier JR; Marovich MA; Kibuuka HN; Bailer RT; Koup RA; Robb ML; Michael NL; Kim JH; Ratto-Kim S
    Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13439-44. PubMed ID: 25197078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 T-cell vaccines: evaluating the next step.
    Pantaleo G
    Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
    Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
    Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.
    Shiver JW; Emini EA
    Annu Rev Med; 2004; 55():355-72. PubMed ID: 14746526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
    Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques.
    Murakowski DK; Barton JP; Peter L; Chandrashekar A; Bondzie E; Gao A; Barouch DH; Chakraborty AK
    Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33514660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ebola virus vaccine: benefit and risks of adenovirus-based vectors.
    Mennechet FJ; Tran TT; Eichholz K; van de Perre P; Kremer EJ
    Expert Rev Vaccines; 2015; 14(11):1471-8. PubMed ID: 26325242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccines in infants and children.
    Lambert JS
    Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
    Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic and prophylactic DNA vaccines for HIV-1.
    Ramirez LA; Arango T; Boyer J
    Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.
    Shu Y; Winfrey S; Yang ZY; Xu L; Rao SS; Srivastava I; Barnett SW; Nabel GJ; Mascola JR
    Vaccine; 2007 Feb; 25(8):1398-408. PubMed ID: 17113201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.
    D'Souza MP; Frahm N
    AIDS; 2010 Mar; 24(6):803-9. PubMed ID: 20168203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.